About
ViruCure Therapeutics is a biotechnology company that develops NADAV, an oncolytic Newcastle disease virus (NDV) platform for the treatment of a wide range of cancer types. The NADAV technology works through the highly selective, replicative, and safe oncolytic effect of NDV in humans. The proprietary NDV strain specifically targets cancerous cells and then replicates itself, creating progeny viruses, which then target and infect others nearby, as well as distal cancerous cells (metastases), throughout the body. NADAV appears to work by causing cell death of the infected tumor cells and by triggering the host's immune response towards the cancerous cells by activating the anti-tumoral immune response. This oncolytic amplification effect is achieved with very low toxicity because NADAV specifically destroys the tumor cells and does not attack normal tissues. Furthermore, since NDV is an avian virus, it has not exhibited any pathological effects or severe illnesses in humans in over 40 years of research. The initial targeted therapies for the platform are currently glioblastoma multiforme and lung cancer patients. This proprietary NDV technology was developed at the Hebrew University of Jerusalem.
Funding history · 1 round · — total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is the primary focus of ViruCure Therapeutics?
- ViruCure Therapeutics is a biotechnology company focused on developing NADAV, an oncolytic Newcastle disease virus (NDV) platform for treating various cancer types.
- What is the operational status of ViruCure Therapeutics?
- According to startupim data, ViruCure Therapeutics is currently inactive and ceased operations in December 2024.
- When was ViruCure Therapeutics founded?
- ViruCure Therapeutics was founded in September 2016.
- Where is ViruCure Therapeutics headquartered?
- ViruCure Therapeutics is headquartered in Jerusalem, Israel.
- What is the core technology developed by ViruCure Therapeutics?
- ViruCure Therapeutics developed the NADAV technology, which utilizes a proprietary Newcastle disease virus (NDV) strain to selectively target, replicate within, and destroy cancerous cells while activating the host's anti-tumoral immune response.
- What types of cancer are initially targeted by ViruCure Therapeutics' NADAV platform?
- The initial targeted therapies for ViruCure Therapeutics' NADAV platform are glioblastoma multiforme and lung cancer patients.
- From which institution was ViruCure Therapeutics' proprietary NDV technology developed?
- ViruCure Therapeutics' proprietary NDV technology was developed at the Hebrew University of Jerusalem.
- What was the last known funding round for ViruCure Therapeutics?
- ViruCure Therapeutics completed a Seed round in January 2017, with undisclosed investor(s).
- How many employees did ViruCure Therapeutics have?
- ViruCure Therapeutics had between 1 and 10 employees, with an exact count of 1 according to startupim data.